PARIS--(Marketwired - Aug 30, 2013) - NANOBIOTIX (the "Company") (EURONEXT PARIS: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has published today its half year results for the six month period ended 30 June 2013 (HY1). Half year highlights include:
Financial highlights:
Main operational highlights:
Post period end main highlights:
Laurent Levy, Chief Executive Officer at Nanobiotix, said:
"We have made excellent clinical progress in the period, beyond what we originally expected, and we would like to accelerate this further if possible. The second half of the year started well and we expect the initiation of the new clinical trial and the reporting of trial results in the period.
We continue to control costs tightly and have focused on strengthening the Company's structure and governance during the period. We have also received a grant from the Bpifrance which not only acknowledges the potential impact of our technology in cancer treatment, but also is helpful in managing the cash flow.
Our strategy is to seek further international collaborations that will allow us to provide sustainable company growth, but we also want to drive progress forward ourselves, with the continued support of our shareholders. As part of our internal plans, we will continue to enhance the operational and commercial experience of the Supervisory Board and management team as we bring our NanoXray products through the clinic and onto the market."
CEO's Operational Report
Overview
Excerpt from:
Nanobiotix Half Year Results for the Period Ended 30 June 2013